Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06283719 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 265 participants planned, started 2024-09-02 and due to reach its primary completion in 2026-04. Interventions recorded: ZG006. Conditions listed: Small Cell Lung Cancer, Neuroendocrine Cancer. No results are recorded here; the registry entry is the source.